Radiotherapy with or without temozolomide in elderly patients aged >= 70 years with glioblastoma

Creative Commons License

Metcalfe E., Karaoglanoglu O., Akyazici E.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, vol.20, no.3, pp.251-255, 2016 (ESCI) identifier identifier identifier


Introduction: Although the recommended optimal treatment of glioblastoma multiforme (GBM) is adjuvant chemoradiotherapy, trials in GBM have excluded patients older than 70 years. In this study, we aimed to assess overall survival (OS) and prognostic factors in elderly patients (>= 70 years) with newly diagnosed GBM treated with radiotherapy (RT) +/- concurrent/adjuvant temozolomide (TMZ).